1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Insmed Planning 2025 Launch For Brensocatib In Bronchiectasis

 
• By Alaric DeArment

The drug maker anticipates a smooth regulatory path and has already begun to rapidly expand its sales force across most of the US.

• Source: Shutterstock

Insmed Incorporated plans to build on its success launching the antibacterial drug Arikayce (amikacin liposome inhalation suspension) as it moves toward regulatory filings and anticipated launch of brensocatib in non-cystic fibrosis bronchiectasis, following the announcement of positive Phase III trial results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D